ASK PHARM(SZ:002755) Xin Lang Cai Jing·2025-10-29 01:20Core Insights - The company reported a total operating revenue of 1.434 billion yuan and a net profit attributable to shareholders of 223 million yuan for Q3 2025 [1] - The net cash inflow from operating activities was 602 million yuan [1] Financial Performance - The latest debt-to-asset ratio is 26.25%, an increase of 5.29 percentage points compared to the same period last year [3] - The latest gross profit margin is 79.80%, which is a decrease of 1.89 percentage points from the previous quarter and a decrease of 2.03 percentage points from the same period last year [3] - The latest return on equity (ROE) is 6.97% [3] - The diluted earnings per share (EPS) is 0.24 yuan [3] - The total asset turnover ratio is 0.34 times, a decrease of 0.03 times compared to the same period last year, representing a year-on-year decline of 8.70% [3] - The inventory turnover ratio is 1.79 times [3] Shareholder Structure - The number of shareholders is 27,200, with the top ten shareholders holding a total of 743 million shares, accounting for 80.04% of the total share capital [3] - The top ten shareholders and their holdings are as follows: - Nanjing Aosaikang Investment Management Co., Ltd.: 34.2% - Zhongyi Weiye Holdings Co., Ltd.: 12.7% - Jiangsu Suyang Investment Industry Co., Ltd.: 12.6% - Weirui Development Co., Ltd.: 12.2% - Nanjing Haiji Investment Management Co., Ltd.: 2.94% - Industrial Bank Co., Ltd. - Yongying Medical Innovation Mixed Fund: 2.26% - CITIC Bank Co., Ltd. - Yongying Ruixin Mixed Fund: 1.01% - Hong Kong Central Clearing Limited: 0.82% - Zheshang Bank Co., Ltd. - Yongying Stable Enhanced Bond Fund: 0.62% - Bank of China Co., Ltd. - E Fund Healthcare Industry Mixed Fund: 0.62% [3]